key: cord-0858295-brdew21g
authors: Lee, Jeong-a; Kim, Yeni; Choi, Jun Yong
title: Impact of the COVID-19 Pandemic on HIV Services in Korea: Results from a Cross-Sectional Online Survey
date: 2021-12-20
journal: Infect Chemother
DOI: 10.3947/ic.2021.0112
sha: 5f63d7f65630560340ea7644ba1258a7c21a72bb
doc_id: 858295
cord_uid: brdew21g

BACKGROUND: Globally, the coronavirus disease 2019 (COVID-19) pandemic has compromised human immunodeficiency virus (HIV) services. The study aimed to assess the impact of COVID-19 on the access and delivery of HIV care in Korea. MATERIALS AND METHODS: People living with HIV (PLHIV), people at risk of HIV (PAR) and prescribers of HIV care were recruited through a patient advocacy group, online communities for men who have sex with men (MSM) and a HIV care center for a web-based survey between October 22 and November 26, 2020. The survey compared the frequency of hospital/clinic visits, HIV-related testing, access to antiretroviral therapy (ART) or preventive medications, and experience with telehealth services by PLHIV and PAR between the pre-pandemic and pandemic eras. RESULTS: One hundred and twelve PLHIV (mean age: 38.5 ± 10.2 years), 174 PAR (mean age: 33.5 ± 8.0 years) and 9 prescribers participated the survey; ≥97% of the PLHIV and PAR were male. A greater proportion of PAR than PLHIV reported a decrease in the frequency of hospital/clinical visits (59.2% vs. 17.0%) and HIV-related testing (50.6% vs. 6.3%) since COVID-19. Among PAR, not engaging or engaging less in high-risk behaviors was the most frequently cited reason (51.1%) for decreased frequency of HIV-related tests. A substantial proportion of PLHIV (12.5%) and PAR (50.0%) experienced interrupted use of ART and HIV preventive medications, respectively. A substantial proportion of PLHIV (35.7%) and PAR (62.5%) were concerned about the long-term accessibility of HIV care, however, >90% had not used any types of telehealth services during the pandemic. CONCLUSION: Overall, COVID-19 has negatively impacted the access and delivery of HIV services in Korea, especially HIV-related testing for PAR. Our findings highlight the need to develop strategies to mitigate the interrupted HIV care.

The coronavirus disease 2019 (COVID- 19) pandemic has imposed burden on the public healthcare systems, exhausting resources for other diseases managed at the national level,

The protocol and questionnaire forms of the study were assessed by the international, independent institutional review board (IRB) Pearl IRB TM and were exempted from IRB review for the period of which the data were being used in the study. All study participants provided informed consent. and measures to curb COVID-19 have disrupted patient journeys for these diseases globally, including human immunodeficiency virus (HIV) infections [1, 2] . A global app-based survey of gay men or men who have sex with men (MSM) reported that of 473 people living with HIV (PLHIV), 23.5% lost access to HIV care provider and 18% had issues with drug refill or access to antiretroviral therapy (ART) since the pandemic [3] . A survey of 317 PLHIV mainly from Belgium and Brazil reported that 17.7% had difficulties obtaining antiretroviral (ARV) medications because of COVID-19-related measures [4] . In a pan-European survey of 19 HIV experts, 42.1% responded that ARV medication procurement might be affected by COVID-19 in their countries [5] . Similarly, the pandemic has affected access to HIV preventive care for people at risk of HIV (PAR). Santos et al. showed that a substantial proportion of 2,247 HIVnegative PAR felt that COVID-19 affected their access to onsite HIV testing (70%), self-test kits (81%), post-exposure prophylaxis (PEP; 83%), or pre-exposure prophylaxis (PrEP; 79%) [3] . A similar survey of PrEP users (N = 406) in the United States showed that 32.0% of users discontinued PrEP during shelter-in-place orders due to COVID-19 [6] .

The interrupted HIV services may subsequently stagnate the global progression towards meeting the Joint United Nations Programme on HIV/acquired immune deficiency syndrome (AIDS) (UNAIDS) 95-95-95 goals and increase HIV-related deaths and HIV transmission [7] . According to UNAIDS, the number of PLHIV currently on treatment declined from January to June 2020 globally [7, 8] . A model analyzing the impact of COVID-19 on HIV services in middle-and low-income countries estimated that COVID-19 would disrupt ART use and increase HIV-related deaths by 10% when compared with a pre-pandemic setting [9] . A similar modeling study in sub-Saharan Africa demonstrated that a 6-month interrupted supply of ART in 50% of the PLHIV population would increase HIV-related deaths by 1.6 times over a year. The study also estimated that interrupted ART use could increase motherto-child transmission of HIV by approximately 1.6 times [10] .

In Korea, HIV diagnosis has been suboptimal. In 2019, 35.2% of PLHIV were estimated to be undiagnosed [11] . In the pre-pandemic era, the incidence of HIV infection was increasing: the annual number of new HIV infection cases increased from 839 in 2008 to 1,222 in 2019 [12] . However, the number of new cases decreased to 1,016 in 2020 [13] . Given the limited local evidence on the impact of COVID-19 on HIV services, assessing the impact of COVID-19 on HIV treatment and prevention in Korea would enable various stakeholders (e.g. the government, prescribers, and patient advocates) to make informed decisions to mitigate these impacts. Therefore, the study aims to assess the impact of COVID-19 on HIV services in Korea and identify key challenges to the access and delivery of HIV services by PLHIV/PAR and prescribers, respectively.

A web-based online survey was conducted among PLHIV, PAR and prescribers in Korea between October 22 and November 26, 2020. This was part of a pan-Asian regional survey rolled out in 10 countries (Hong Kong, India, Japan, Malaysia, the Philippines, Singapore, Korea, Taiwan, Thailand and Vietnam). Upon assessment by the international, independent institutional review board (IRB) Pearl IRB TM , the protocol and survey forms (#20-KANT-238) were exempted from IRB review for the period of which the data were being used in the study.

PLHIV and PAR were invited to participate in the survey through the websites of the following HIV/AIDS patient advocacy group and online communities for MSM: ivan Stop HIV/AIDS Project (iSHAP), IVANCITY, and LOVE4ONE. Participants aged ≥ 21 years who resided in Korea and provided informed consent were included in the study. PLHIV were defined as participants who reported to be HIV-positive. PAR were defined as those who reported to be HIV-negative but engaged in at least 1 HIV-related risky behavior. Participants who were HIVnegative and did not engage in HIV-related risky behaviors were excluded. Prescribers were invited to participate in the survey via email. The number of unique clicks for the links to the questionnaires and number of completed responses are available in Supplementary Table 1.

Three versions of the survey form were developed for PLHIV, PAR and prescribers, respectively. Each form consisted of 2 sections. A 2-minute-long screening section collected information on the participant's demographics and history of using/delivering HIV services (including country of residence, age groups, gender, sexual orientation, a history of HIV diagnosis, presence of risky behaviors, and a history of ART or HIV preventive interventions for PLHIV and PAR, and country of practice, current specialty, type of hospital/clinic, and expertise in managing PLHIV and PAR for prescribers). A 10-minute-long main questionnaire measured the impact of COVID-19 on HIV care access among PLHIV and PAR, and HIV care delivery by prescribers ( Table 1) . The survey was developed in English and translated into Korean. The translation was proofread by a linguist from a translation company, who was a native Korean speaker.

Descriptive analyses of participants' characteristics and responses were performed. Continuous measurements were presented using mean and standard deviations (SD). For nominal and ordinal scale measurements, the numbers of participants choosing each option were summarized with percentages. The authors considered results of any item that was answered by ≥30 respondents as robust; the threshold was calculated using the numbers of PLHIV and infectious diseases doctors in Korea. PrEP, pre-exposure prophylaxis; PEP, post-exposure prophylaxis.

The analyses included 112 PLHIV and 174 PAR ( 

Among PLHIV and PAR, 19 (17.0%) and 103 (59.2%) reported that they visited hospitals/ clinics less frequently or stopped visiting them completely when compared with the pre-COVID period, respectively (Fig. 1A) . From the prescribers' perspective, 4 (44.4%) and 7 (77.8%) prescribers reported a decrease in hospital/clinic visits or rescheduling of visits due to closure of clinics experienced by PLHIV and PAR, respectively, at their clinics ( Table 3 ).

Of 7 PLHIV (6.3%) who reported a decrease in the frequency of HIV-related tests, 5 (71.4%) attributed the decrease to the concern of contracting COVID-19 at hospitals/clinics (Fig. 1B,  1C) . Among PAR, 88 (50.6%) reported a decrease in the frequency of HIV-related tests. The most common reason was not engaging or engaging less in high-risk behaviors (Fig. 1B, 1D) . A decrease in the frequency of HIV-related tests for PLHIV and for PAR was reported by 2 prescribers each ( Table 3 ).

Among PLHIV, 14 (12.5%) experienced interrupted ART use. The key reasons for a decrease in the frequency of ARV medications use (N = 6) were travel constraints (50.0%) and concerns over getting COVID-19 at hospitals/clinics (50.0%) ( Fig. 2A, 2B) . Of 8 PAR who were on HIV preventive medications before the pandemic, 2 (25.0%) decreased the frequency of taking the medications and 2 (25.0%) stopped taking the medications completely. The main reason was not engaging or engaging less in high-risk behaviors (Fig. 2C, 2D) . Four prescribers (44.4%) reported a decrease in the frequency of ARV drugs prescription refill by PLHIV (Table 3) , and they attributed this change to patient's willingness/preferences and travel constraint. A prescriber (14.3%) reported decreased accessibility of HIV preventive medications during COVID-19 ( Table 3 ) without specifying the reasons.

Substantial proportions of PLHIV (35.7%) and PAR (62.5%) were concerned about the longterm accessibility of ART/HIV preventive medicine (Fig. 3A) . The majority of PLHIV and PAR reported having never received telehealth services (91.3%) (Fig. 3B) . Phone consultation (43.7%) was the most preferred type of telehealth services among PLHIV and PAR (Fig. 3C) . Seven (77.8%) prescribers had provided phone consultation and 5 (55.6%) prescribers anticipated the use of telehealth services to increase in the future, mainly driven by its ability to reach more patients and improve clinical workflows and efficiency ( Table 3) .

Globally, COVID-19 and the measures to prevent its spread have interrupted HIV services for PLHIV and PAR [3, 5, 14] . Our study highlighted that in Korea, COVID-19 has more severely affected the utilization of HIV services by PAR than by PLHIV. The survey showed that ART use by PLHIV was moderately affected (12.5%), which is comparable to what were reported by PLHIV around the globe (18%) [3, 4] . The majority of PAR indicated that they had less frequent or no hospital/clinic visits and received HIV-related tests less frequently during COVID-19 compared with the pre-COVID period. Among 8 PAR who were on HIV preventive https://icjournal.org https://doi.org/10.3947/ic.2021.0112 conducted in the US and around the globe [3, 6, 14] . A self-reported decrease in high-risk behaviors among PAR is supported by Sanchez et al, which reported that since COVID-19, MSM had less opportunities to have sex (68.0%), had fewer sex partners (51.3%), and used dating apps to meet in person less frequently (48.8%) [14] . However, in Brawley et al. 2020 , 32% of PAR (N = 406) stopped PrEP after the implementation of COVID-19 restriction measures, although the vast majority of PrEP users reported no change in risky behaviors and 88.9% of PrEP providers recommended against dose modification [6] . Therefore, our survey, together with the results of the studies around the globe, warrants HIV prescribers to carefully monitor risky behaviors of PAR and educate PAR on the value of regular HIV-related tests and adherence to HIV preventive medications even during the pandemic. Also, these results indicate that the decrease in the number of new HIV cases from 2019 to 2020 should be interpreted with caution [13] , as it could be attributable to a decrease in the number of Our results also demonstrated that for both PLHIV and PAR, concerns of contracting COVID-19 in hospitals/clinics and travel constraints were other key reasons for decreased frequency of HIV-related testing and changes to the use of ARV/HIV preventive medications. In Korea, HIV testing is mainly managed at public health centers, and since the pandemic, these centers have been serving as COVID-19 screening stations [15] . This could have heightened PAR's fear of contracting COVID-19 and subsequently discouraged them from coming forward for HIV testing. The consequence of decreased frequency of HIV testing at facilities is highlighted by a nationwide analysis in Korea, which reported that the number of subjects who came forward for HIV testing at public health centers decreased by 59.4% from 2019 to 2020 [16] . These results suggest that strategies circumventing the need for hospital/ clinic visits would alleviate the COVID-19 related disruptions to HIV services in Korea, particularly around HIV-related testing and delivery of HIV preventive medications for PAR. During the pandemic, HIV self-testing and telehealth services have been implemented in the China, US, Brazil, India, and other countries to maintain HIV testing uptake and allow access to ARV and HIV preventive medications among PLHIV/PAR [17] [18] [19] [20] [21] . A cross-sectional study of 658 MSM in China reported that the proportion of MSM who received HIV testing using a self-test kit significantly increased from 41.6% to 52.1% (P = 0.038), and the proportion of MSM receiving HIV testing within 3 months before and during COVID-19 measures were in place remained unchanged (N = 255 vs. N = 261) despite limited access to routine facilitybased testing services when the COVID-19 measures were implemented [21] . According to our survey, both PLHIV/PAR in Korea had limited experience with telehealth services, and PLHIV/PAR in Korea are unlikely to be familiar with HIV self-test kits, which only became reimbursable in September 2019 [22] . Therefore, concerted efforts would be needed from the government, healthcare industry, prescribers and patient advocacy groups to establish infrastructure for HIV self-testing and telehealth, train prescribers to design and deliver telehealth services, and educate patients on the accessibility and usefulness of self-testing and telehealth services.

Prescribers reported a decrease in the number of PLHIV and PAR per month compared with the pre-COVID period. While this tallied with the decreased frequency of hospital/clinic visits reported by PLHIV and PAR, the reduction in the provision of HIV services by prescribers could also reflect the reallocation of the public healthcare resources from infectious diseases to COVID-19. In Korea, a substantial proportion of PLHIV are managed at public hospitals, and these institutions have become nationally-designated treatment facilities for COVID-19 since the pandemic [15] . As a result, the health workforce originally designated for infectious diseases in these institutions might have been reallocated to COVID-19 in response to the urgency of treating COVID-19 patients.

Some limitations of the study should be considered. The format of online survey might have led to selection bias against older respondents, who might not be very familiar with the internet. The translated survey forms were not validated by experts in the field prior to the study to check if the questions conform to the Korean cultural context. The situations reflected in the study results may also be transient due to the evolving epidemiology of COVID-19. Finally, the study was based on a small sample size, especially prescribers, and was drawn using convenience sampling. Therefore, the survey results may not represent the general populations of PLHIV, PAR and prescribers in Korea. Nonetheless, this is the first study assessing the impact of COVID-19 on PLHIV, PAR and prescribers in terms of HIV services in Korea at the time of writing (December 2021).

In conclusion, our study showed negative impacts of COVID-19 on hospital/clinic visits, HIVrelated tests and use of ARV/HIV preventive medications by PLHIV and PAR in Korea. The government, healthcare industry, prescribers and patient advocacy groups in Korea should collaborate to identify barriers to HIV care continuum and develop strategies to retain the timely access to HIV services for PLHIV/PAR in Korea.

Fair Allocation of Scarce Medical Resources in the Time of Covid-19

Consequences of COVID-19 crisis for persons with HIV: the impact of social determinants of health

Economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response on a global sample of cisgender gay men and other men who have sex with men

Impact of the COVID-19 pandemic on the medical follow-up and psychosocial well-being of people living with HIV: a cross-sectional survey

HIV care in times of the COVID-19 crisis -Where are we now in Central and Eastern Europe?

Impact of COVID-19 related shelter-in-place orders on PrEP access, usage and HIV risk behaviors in the United States

UNAIDS. Global AIDS Strategy 2021-2026 End Inequalities End AIDS. Available at

90-90-90: good progress, but the world is off-track for hitting the 2020 targets

Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models

Estimation of the Number of HIV Infections and Time to Diagnosis in the Korea

Korea Disease Control and Prevention Agency. HIV/AIDS notifications in Korea

Korea Disease Control and Prevention Agency. HIV/AIDS notifications in Korea

Characterizing the impact of COVID-19 on men who have sex with men across the United States in

Republic of Korea. Patient Treatment & Management

Characteristics of HIV screening tests in public health centers in Korea

Keep it going if you can": HIV service provision for priority populations during the COVID-19 pandemic in

Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV prevention service in Rio de Janeiro-Brazil

HIV self-test during the time of COVID-19

Development of telemedicine infrastructure at an LGBTQ+ clinic to support HIV prevention and care in response to COVID-19

HIV self-testing partially filled the HIV testing gap among men who have sex with men in China during the COVID-19 pandemic: results from an online survey

Use of Oraquick for HIV and HCV screening, reimbursement to take place from

The authors thank the 3 HIV/AIDS patient advocacy groups: ivan Stop HIV/AIDS Project (iSHAP), IVANCITY, and LOVE4ONE for supporting the survey procedures. The authors also thank Kantar for collecting and analysing the data. The authors thank Min Hee Choi, Ph.D., Costello Medical Singapore Pte Ltd, for medical writing and editorial assistance based on the authors' input and direction.

 Supplementary Table 1 The number of unique clicks for the links to the questionnaires and number of completed questionnaires Click here to view